New Advances in Mitral Regurgitation Devices with Promising Results

Mitral regurgitation (MR) is a frequent valvulopathy and when the optimal medical treatment at maximum tolerated doses is not enough, surgery is the first course of action. And even though edge-to-edge repair with clips has seen substantial improvement, it is currently reserved for those at high risk of surgery. 

However, there is an increasing number of patients that will not benefit from neither of these strategies. This is why different devices have been developed to approach this condition.

A feasibility study was carried out with the system HighLife TSMVR, including 30 patients with moderate to severe or severe MR, symptomatic, and with high or prohibitive risk of surgical valve replacement.

Patients were mean age was 75, and 22 were men. All patients belong to functional class III or IV, and half had been hospitalized for cardiac failure within the last year. Also, 13 patients presented diabetes, 18 hypertension, 15 prior MI, 6 COPD, 21 atrial fibrillation, 8 were in resynchronization therapy and 5 had a pacemaker. Ejection fraction was 43%, and most presented secondary MR. 

Successful implantation was achieved in 27 patients, with final gradient 3.9 mmHg. No patient presented MR or moderate or severe leaks, neither right ventricular outflow tract obstruction. Three patients experienced pericardial effusion, one required conversion to surgery and there was one device embolization. Mean hospital stay was 8 days. 

Read also: SAFE-TAVI Study: Safety and Efficacy of the Pressure Sensor and Pacing Guidewire.

After one year, there were 5 deaths, only 2 were for cardiovascular causes. Two presented acute MI, one had a stroke and 7 needed hospitalization for cardiac failure. No patient required a reintervention and they all saw improved functional class and quality of life. ECG analysis revealed a 5.1 mmHg gradient and neither presented moderate or severe MR or left ventricular outflow tract obstruction. 

Conclusion

To conclude, one year outcomes with HighLife TSMVR have shown technical success, excellent valve function and the absence of left ventricular outflow tract obstruction. We should highlight the lack of reintervention, even though we recognize the importance of a longer followup to confirm these findings. 

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Original Title: 1-Year Outcomes Following Transfemoral Transseptal Transcatheter Mitral Valve Replacement. The HighLife TSMVR Feasibility Study. 

Reference: Leonhard-Moritz Schneider, et al. Article in Press J Am Coll Cardiol Intv 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

Prospective Analysis of the Feasibility of the PASCAL System for Transcatheter Mitral Repair: OneForAll Registry

Courtesy of Dr. Juan Manuel Pérez. Mitral transcatheter edge-to-edge repair (M-TEER) is an effective option for patients with severe mitral regurgitation who are at high...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...